Hugel targets wider Singapore demand beyond aesthetics

Clinical trials could broaden botulinum toxin demand beyond cosmetic treatments.

Hugel Inc. is looking to widen demand for its botulinum toxin products in Singapore beyond aesthetic medicine as it develops additional therapeutic indications.

In an interview during the 2026 Gangwon Biohealth Press Tour, Lee Yeon Kyung, Director and Production Group 2 Leader at Hugel, said the company is conducting clinical trials for uses including ptosis correction and polio treatment, alongside applications such as square-jaw reduction.

The shift could expand the product’s addressable market beyond cosmetic procedures and into a broader range of clinical settings.

Hugel already exports its botulinum toxin products to Singapore, giving the company an existing market base for any future expansion in approved indications.

“We are currently exporting our products to the Singapore market, and as far as I know, we have not received any complaints from Singapore,” Lee said.

She added that Hugel’s manufacturing base in South Korea benefits from pharmaceutical production standards, specialised facilities and trained workers for injectable medicines.

Lee cited Korean good manufacturing practice requirements as part of that manufacturing foundation.

“I believe our strength lies in the fact that these are pharmaceuticals you can trust and rely on,” she said.

For healthcare providers and distributors, the commercial significance lies in whether botulinum toxin can move beyond its established cosmetic use and gain wider uptake for therapeutic applications.

Any expansion in Singapore would still depend on the outcome of ongoing clinical trials and the regulatory acceptance of additional indications.

For Hugel, the next stage of growth in the market is therefore less about entering Singapore and more about widening where and how its existing products can be used.

Follow the link for more news on

pharmaceuticals

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia